AOD-9604 Frequently Asked Questions

AOD-9604 is a synthetic peptide comprising the C-terminal fragment of human growth hormone (amino acids 176-191) with an additional tyrosine residue at the N-terminus. It was originally developed to isolate the lipolytic activity of growth hormone from its growth-promoting effects. Peptides Pharma AOD-9604 is formulated at >99% purity in a lyophilized vial.

Research suggests AOD-9604 stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat formation) through mechanisms similar to the fat-metabolising region of growth hormone. It is thought to act via the beta-3 adrenergic receptor pathway without affecting blood sugar levels or tissue growth. These findings are from preclinical and clinical studies and do not constitute medical claims.

AOD-9604 is studied in research related to fat metabolism, body composition, obesity mechanisms, cartilage repair, and osteoarthritis. Its ability to influence adipose tissue without affecting glucose homeostasis makes it a valuable compound in metabolic research protocols.

Peptides Pharma AOD-9604 is manufactured to >99% purity in GMP-certified, ISO 7 cleanroom facilities. Every batch undergoes independent HPLC and mass spectrometry verification. A Certificate of Analysis confirming identity, purity, and sterility is available for each batch.

Lyophilized AOD-9604 should be stored at -20°C for long-term storage or 2-8°C for short-term use. Keep away from direct light and moisture. Once reconstituted, the solution should be refrigerated at 2-8°C and used within 28 days.

Reconstitute AOD-9604 by slowly injecting bacteriostatic water down the inside wall of the vial. Do not shake or agitate vigorously — gently swirl until the powder is fully dissolved. The volume of bacteriostatic water used will determine the final concentration for dosing calculations.

Once reconstituted with bacteriostatic water, AOD-9604 solution should be stored refrigerated at 2-8°C and is typically stable for up to 28 days. Always use aseptic technique when drawing from the vial to maintain sterility throughout the usage period.

Yes. Peptides Pharma AOD-9604 is supplied strictly for laboratory and research use. It is not approved as a medicine and is not intended for human therapeutic application. All research should be conducted in accordance with applicable regulations and institutional guidelines.

Research protocols in published literature have used various dosing ranges depending on the study model and objectives. Researchers should consult peer-reviewed publications relevant to their specific research area for appropriate dosing parameters. Peptides Pharma does not provide individualised dosing advice.

AOD-9604 has been studied in combination with other metabolic peptides in some research protocols. Its distinct mechanism of action — targeting fat metabolism without affecting IGF-1 — may complement peptides that operate through different pathways. Researchers should design combination protocols based on published literature and relevant guidelines.

Peptides Pharma ships AOD-9604 in lyophilized form with appropriate cold-chain packaging to maintain stability during transit. Orders are dispatched promptly with tracked delivery to ensure the product arrives in optimal condition for research use.